SPHERA FUNDS MANAGEMENT LTD.
TEL AVIV, L3 · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$660.4M2026 Q3+ $47.1M options (notional, not included)
Positions113
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.33.0%
What Changed This Quarter?
Top Holdings
MLYS
Mineralys Therapeutics
4.7%
TEVA
Teva Pharmaceutical Industries
4.6%
ALNY
Alnylam Pharmaceuticals
4.2%
CYTK
Cytokinetics
3.4%
SOXX
Ishares Tr
3.0%
BBIO
BridgeBio Pharma
2.9%
TSEM
Tower Semiconductor
2.7%
SNDX
Syndax Pharmaceuticals
2.7%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.